[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631995":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":22,"interventions":35,"overallOfficials":13,"centralContacts":44,"locations":50,"responsibleParty":67,"collaborators":13,"id":69,"slug":13,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":13,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":13,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":13,"overallStatus":88,"whyStopped":13,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Wecare Probiotics Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in body weight following the intervention","Body weight will be assessed using a calibrated digital scale under standardized conditions","Baseline (Week 0) and Weeks 4, 8, and 12",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"SINGLE",[21],"PARTICIPANT",[23,29],{"label":24,"type":25,"description":26,"interventionNames":27},"Probiotic group","EXPERIMENTAL","Pasteurized Akkermansia muciniphila Akk11 capsule, 34 billion TFU\u002Fday",[28],"Dietary Supplement: Probiotic",{"label":30,"type":31,"description":32,"interventionNames":33},"Placebo group","PLACEBO_COMPARATOR","Placebo capsule, one capsules\u002Fday",[34],"Dietary Supplement: Placebo",[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":13},"DIETARY_SUPPLEMENT","Probiotic","The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)",[24],{"type":37,"name":42,"description":39,"armGroupLabels":43,"otherNames":13},"Placebo",[30],[45],{"name":46,"role":47,"phone":48,"phoneExt":13,"email":49},"Ying Wu, doctor","CONTACT","18639283502","yingwu@haust.edu.cn",[51],{"facility":52,"status":13,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"The School of Food and Bioengineering, Henan University of Science and Technolog","Luoyang","Henan","471000","China","CN",{"type":59,"coordinates":60},"Point",[61,62],112.43684,34.67345,{"lat":62,"lon":61},[65],{"name":46,"role":47,"phone":48,"phoneExt":66,"email":49},"+86",{"type":68,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100631995",false,"NCT07507929","Probiotic for Weight Management in Overweight and Obese Adults","Effectiveness and Safety of Inactivated Akkermansia Muciniphila Akk11 (34B) on Weight and Energy Metabolism in Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 24 kg\u002Fm²;\n2. Able and willing to provide written informed consent;\n3. Willing to comply with the study protocol and required restrictions, including adherence to a low-carbohydrate, energy-restricted diet;\n4. No intention to conceive from 14 days prior to screening until 6 months after study completion, and agreement to use effective contraception during this period\n\nExclusion Criteria:\n\n1. Recent use of products with similar functions to the investigational product that may interfere with study outcomes;\n2. History of psychiatric or neurological disorders, celiac disease, lactose intolerance, or known allergies;\n3. Pregnant or breastfeeding women, or those planning to become pregnant during the study period;\n4. Diagnosis of irritable bowel syndrome (IBS), ulcerative colitis, liver cirrhosis, or diabetes mellitus;\n5. Use of antibiotics within 3 months prior to screening;\n6. Inability to comply with the study protocol, including failure to take the investigational product as required or attend scheduled follow-up visits;\n7. Smoking more than 10 cigarettes per day;\n8. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",true,"ALL","18 Years","65 Years",{"count":80,"type":81},76,"ESTIMATED","INTERVENTIONAL",[84],"NA","To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and basal metabolic rate) and serum lipid parameters (TC, LDL-C, HDL-C, and TG) in overweight and obese adults.",[87],"Obesity","NOT_YET_RECRUITING","2026-03-27",{"date":91,"type":92},"2026-04-02","ACTUAL",{"date":94,"type":81},"2026-03-20",{"date":96,"type":81},"2026-12-30",{"name":5,"class":6},1]